Overview of Methamphetamine-Associated Pulmonary Arterial Hypertension

Area of Science:

• Cardiology
• Pulmonology
• Public Health

Background:

• Global methamphetamine use presents a significant public health challenge.
• Methamphetamine use is strongly associated with pulmonary arterial hypertension (MA-PAH).
• MA-PAH incidence is rising, posing an imminent threat to global health.

Purpose of the Study:

• To provide a comprehensive review of methamphetamine-associated pulmonary arterial hypertension (MA-PAH).
• To explore the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of MA-PAH.
• To identify knowledge gaps for future research directions.

Main Methods:

• Systematic literature review of MA-PAH.
• Analysis of epidemiological data.
• Synthesis of current understanding of pathophysiology and clinical management.

Main Results:

• MA-PAH pathogenesis involves complex molecular pathways including serotonin signaling, oxidative stress, and vascular remodeling.
• MA-PAH presents with a more severe clinical and hemodynamic profile than idiopathic pulmonary arterial hypertension.
• Effective management requires a multimodal approach: pulmonary vasodilators, methamphetamine cessation, and rehabilitation programs.

Conclusions:

• Current understanding of MA-PAH pathogenesis and treatment is evolving.
• Further research is needed to address diagnostic accuracy and optimize therapeutic strategies.
• Addressing knowledge gaps is crucial for managing the increasing burden of MA-PAH.